Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Haematologica|June 12, 2025
Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemiaJunji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, et al.
Pediatric Blood & Cancer|December 6, 2023
High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factorTakahiro Aoki, Norio Shiba, Shinichi Tsujimoto, et al.
Genes, Chromosomes & Cancer|January 8, 2017
Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndromeYusuke Hara, Norio Shiba, Kentaro Ohki, et al.
Bone Marrow Transplantation|July 1, 2018
Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive casesDaisuke Tomizawa, Masanori Yoshida, Tadakazu Kondo, et al.
British Journal of Haematology|April 28, 2020
Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 studyTakahiro Aoki, Hiroyuki Takahashi, Shiro Tanaka, et al.
Haematologica|March 18, 2021
Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemiaTaeko Kaburagi, Genki Yamato, Norio Shiba, et al.
Genes, Chromosomes & Cancer|November 30, 2022
UBTF-internal tandem duplication as a novel poor prognostic factor in pediatric acute myeloid leukemiaTaeko Kaburagi, Norio Shiba, Genki Yamato, et al.
NPJ Genomic Medicine|February 17, 2024
Assessing the efficacy of target adaptive sampling long-read sequencing through hereditary cancer patient genomesWataru Nakamura, Makoto Hirata, Satoyo Oda, et al.
Blood Advances|January 10, 2022
Genome-wide DNA methylation analysis in pediatric acute myeloid leukemiaGenki Yamato, Tomoko Kawai, Norio Shiba, et al.
Japanese Journal of Clinical Oncology|July 9, 2022
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)Daisuke Tomizawa, Shin-Ichi Tsujimoto, Shiro Tanaka, et al.
Pageof 6